Cai D, et al. - Researchers investigated KRAS co-mutation subtypes and their prognosis value in advanced Chinese non-small cell lung cancer (NSCLC) patients. From Xiangya hospital, they screened 1,126 Chinese advanced NSCLC patients using capture-based ultra-deep sequencing. Of these, 84 cases exhibited KRAS mutation (7.5%). All of these had non-squamous NSCLC and were provided pemetrexed plus platinum as the first-line treatment. TP53 (29%), TP53/LKB1 (19%), and LKB1 (14%) were the most frequent KRAS co-mutation genes identified. Patients with KRAS co-mutation vs those harboring single KRAS mutation had poorer prognosis. Furthermore, the shortest progression-free survival (PFS) was observed for patients with KPL (KRAS mutated with TP53 and LKB1) subtype, a novel subtype, in all types of KRAS co-mutation patients. Patients with KRAS^G12D mutation exhibited inferior PFS and overall survival (OS) than those with KRAS^G12C mutation or KRAS^G12V mutation. Significantly longer survival was reported for patients in KRAS^G>T type than those in KRAS^G>C type or KRAS^G>A type. These findings suggest that KRAS-mutant lung adenocarcinoma patients could be further stratified into various subgroups via assessing concurrent genomic alterations; these subgroups have distinctive therapeutic responses and differential survival outcomes.